Grosset, Donald G <br/><br/>
Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.  [electronic resource] 

 -  Journal of rehabilitation medicine  Feb 2015 
 - 183-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1651-2081 
<br/><br/><label>Standard No.: </label>10.2340/16501977-1895  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Blepharospasm--drug therapy<br/>Botulinum Toxins, Type A--administration & dosage<br/>Cost Savings<br/>Drug Administration Schedule<br/>Dystonia--drug therapy<br/>Female<br/>Hemifacial Spasm--drug therapy<br/>Humans<br/>Injections, Intramuscular<br/>Male<br/>Neuromuscular Agents--administration & dosage<br/>Torticollis--drug therapy<br/>Treatment Outcome